Prednimustine (NSC-134087, leo 1031) treatment of lymphocytic and lymphocytic-histiocytic lymphomas
- 1 January 1978
- Vol. 41 (1) , 112-116
- https://doi.org/10.1002/1097-0142(197801)41:1<112::aid-cncr2820410117>3.0.co;2-c
Abstract
Nineteen patients with advanced lymphocytic or lymphocytic-histiocytic lyphomas were treated with Prednimustine (NSC-134087, Leo 1031). The median induction dose was 25 mg/m2 a day by mouth (range 11-42). Ten patients had previously received radiation or chemotherapy, or both. Four patients had a complete remission and eleven a partial remission. The median duration of remission was 12.5+ months for complete responders and 5 months for partial responders. Thirteen patients had a moderate myelosuppression. One patient had urticaria and pruritus and refused further treatment.This publication has 9 references indexed in Scilit:
- Recent trends in the treatment of non-Hodgkin's lymphomasPublished by Elsevier ,1976
- Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trialBlood, 1976
- Lymphosarcoma. A comparison of extended to conservative chemotherapyCancer, 1976
- STUDY OF LEO-1031 (NSC-134087) IN LYMPHOCYTIC LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA1976
- THERAPEUTIC EFFECT OF LEO 1031, AN ALKYLATING CORTICOSTEROID ESTER, IN LYMPHOPROLIFERATIVE DISORDERSActa Medica Scandinavica, 1975
- Combination Chemotherapy of Lymphomas Other Than Hodgkin's DiseaseAnnals of Internal Medicine, 1974
- Non-Hodgkin's lymphomas. II. Single agent chemotherapyCancer, 1972
- Combination Chemotherapy in Lymphosarcoma and Reticulum Cell SarcomaBlood, 1969